Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving vaccine performance with adjuvants.

F R Vogel1

  • 1Vaccine and Prevention Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA. fred.vogel@aventis.com.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|June 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The immunogenicity of a cell-derived H7N1 split influenza virion vaccine in mice.

Scandinavian journal of immunology·2009
Same author

Adjuvants in perspective.

Developments in biological standardization·1998
Same author

Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.

Journal of immunology (Baltimore, Md. : 1950)·1997
Same author

Workshop on the control and standardization of nucleic acid vaccines. Bethesda, Maryland, 8 February 1996.

Vaccine·1997
Same author

Role of adjuvants in HIV vaccine design.

Antibiotics and chemotherapy·1996
Same author

Nucleic acid vaccines.

Clinical microbiology reviews·1995
Same journal

Reconsidering ambiguous language in infectious disease consult recommendations.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

New subunit vaccines, like those for HIV and tuberculosis, often need immunologic adjuvants to boost their effectiveness. Adjuvants enhance immune responses, improving vaccine performance and safety.

Area of Science:

  • Vaccinology
  • Immunology
  • Infectious Disease Control

Background:

  • Subunit vaccines, including synthetic and recombinant types, are in development for diseases like HIV and tuberculosis.
  • While safer than whole-cell vaccines, subunit vaccines may have weaker immunogenicity due to antigen purity and lack of inherent immune-stimulating components.

Purpose of the Study:

  • To explore the role of immunologic adjuvants in enhancing the immunogenicity of subunit vaccines.
  • To discuss the selection criteria for adjuvants based on desired immune response and administration route.

Main Methods:

  • Review of current vaccine development strategies focusing on subunit antigens.
  • Analysis of the mechanisms and applications of immunologic adjuvants in vaccinology.

Related Experiment Videos

Main Results:

  • Subunit vaccines often require potent adjuvants to achieve protective immune responses.
  • Adjuvants can overcome the reduced immunogenicity associated with highly purified vaccine antigens.

Conclusions:

  • Formulating subunit vaccines with appropriate adjuvants is crucial for improving their efficacy.
  • Adjuvant selection should be tailored to the specific vaccine target and desired immune outcome (e.g., antibody, cell-mediated, or mucosal immunity).